|
EP0992506B1
(en)
*
|
1998-10-08 |
2003-08-06 |
Novartis AG |
Process for the sulfurisation of phosphorus-containing compounds
|
|
US7098325B2
(en)
*
|
1998-10-08 |
2006-08-29 |
Pierre Martin |
Process for the sulfurization of a phosphorus-containing compound
|
|
GB0004889D0
(en)
|
2000-03-01 |
2000-04-19 |
Avecia Ltd |
Synthesis of oligonucleotides
|
|
US6768005B2
(en)
*
|
2000-12-20 |
2004-07-27 |
Avecia Limited |
Process
|
|
WO2002046205A2
(en)
*
|
2000-12-05 |
2002-06-13 |
Avecia Limited |
Process for the preparation of phosphorothionate oligonucleotides
|
|
AR036122A1
(es)
*
|
2001-07-03 |
2004-08-11 |
Avecia Biotechnology Inc |
Un complejo de sal que comprende un n-alquilimidazol y una 1,1-dioxo-1,2-dihidro-1l6-benzo [d]-isotiazol-3-ona y un metodo para sintetizar oligonucleotidos utilizando la quimica de fosforamidita
|
|
JP4825375B2
(ja)
*
|
2001-08-28 |
2011-11-30 |
株式会社 資生堂 |
ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤
|
|
GB0209539D0
(en)
*
|
2002-04-26 |
2002-06-05 |
Avecia Ltd |
Monomer Polymer and process
|
|
WO2005097817A2
(en)
*
|
2004-04-05 |
2005-10-20 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
|
CN104086516B
(zh)
*
|
2014-07-18 |
2016-01-06 |
成都樵枫科技发展有限公司 |
R-(+)-硫代四氢呋喃-2-甲酸的合成方法
|
|
CN110199023A
(zh)
|
2016-12-28 |
2019-09-03 |
第一三共株式会社 |
阿尔波特氏综合症治疗药
|
|
WO2019111791A1
(ja)
*
|
2017-12-07 |
2019-06-13 |
第一三共株式会社 |
ジストロフィン遺伝子のイントロンリテンションを解消するアンチセンスオリゴヌクレオチド
|
|
CN111511915A
(zh)
|
2018-03-09 |
2020-08-07 |
第一三共株式会社 |
糖原病Ia型治疗药
|
|
US20210207136A1
(en)
|
2018-06-13 |
2021-07-08 |
Daiichi Sankyo Company, Limited |
Myocardial dysfunction therapeutic agent
|
|
CA3140438A1
(en)
|
2019-06-05 |
2020-12-10 |
Masatora Fukuda |
Stable target-editing guide rna having chemically modified nucleic acid introduced thereinto
|
|
EP3995153A4
(en)
|
2019-06-26 |
2023-11-22 |
KNC Laboratories Co., Ltd. |
Nucleic acid drug suppressing production of myostatin gene mrna
|
|
BR112021024764A2
(pt)
|
2019-07-12 |
2022-04-19 |
Daiichi Sankyo Co Ltd |
Oligonucleotídeo antissenso capaz de alterar o splicing de pré-mrna de dux4
|
|
WO2021049504A1
(ja)
|
2019-09-10 |
2021-03-18 |
第一三共株式会社 |
肝臓送達用ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲートおよび製造方法
|
|
IL292286A
(en)
|
2019-10-18 |
2022-06-01 |
Daiichi Sankyo Co Ltd |
Production method for bicyclic phosphoramidite
|
|
EP4119167A4
(en)
|
2020-03-11 |
2025-08-06 |
Biocomber Co Ltd |
SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR INDUCING FRAME SHIFT-1 AND COMPOSITION
|
|
JP7722666B2
(ja)
|
2020-07-28 |
2025-08-13 |
神戸天然物化学株式会社 |
アンギオテンシン変換酵素２遺伝子のエクソンのスキッピングを誘導するアンチセンス核酸
|
|
EP4261284A4
(en)
|
2020-12-08 |
2025-07-16 |
Univ Fukuoka |
STABLE TARGET EDITING GUIDE RNA INTO WHICH A CHEMICALLY MODIFIED NUCLEIC ACID HAS BEEN INTRODUCED
|
|
US20240229036A9
(en)
|
2021-02-26 |
2024-07-11 |
Knc Laboratories Co., Ltd. |
Nucleic acid medicine expressing splicing variant of myostatin
|
|
JPWO2023176863A1
(https=)
|
2022-03-16 |
2023-09-21 |
|
|
|
KR20240161967A
(ko)
|
2022-03-16 |
2024-11-13 |
다이이찌 산쿄 가부시키가이샤 |
트랜스페린 수용체 2 의 발현을 억제하는 siRNA
|
|
TW202523839A
(zh)
|
2023-08-25 |
2025-06-16 |
學校法人福岡大學 |
導入有磷酸部修飾之穩定型標靶編輯引導ｒｎａ
|